For patients with HER2 BC, SLC39A1, SLC39A5, SLC39A9 and SLC39A13 high expression suggested a worse OS, but SLC39A6 and SLC39A14 high expression suggested a benefit OS. Here, SLC39A9 is linked to breast cancer.